Locus Biosciences Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
63
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$9M
- Investors
-
13
Locus Biosciences General Information
Description
Developer of bacteriophage-based products designed to precisely remove pathogenic bacteria from the human body. The company's product combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses, enabling physicians to begin treatment quickly, resulting in an efficient medical outcome.
Contact Information
Website
www.locus-bio.comCorporate Office
- 523 Davis Drive
- Suite 350
- Morrisville, NC 27560
- United States
Corporate Office
- 523 Davis Drive
- Suite 350
- Morrisville, NC 27560
- United States
Locus Biosciences Timeline
Locus Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | $9M | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 18-May-2022 | Completed | Generating Revenue | |||
| 7. Debt - General | 30-Jul-2021 | Completed | Generating Revenue | |||
| 6. Debt - General | 01-Oct-2019 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 14-Nov-2017 | Completed | Generating Revenue | |||
| 4. Seed Round | 18-Apr-2016 | Completed | Startup | |||
| 3. Debt - General | 04-Mar-2016 | Completed | Startup | |||
| 2. Debt - General | 05-Nov-2015 | $75K | $75K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
Locus Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 4,391,966 | $0.000100 | 6% | $4.57 | $4.57 | 1x | $4.57 | 36.22% |
| Seed | 447,761 | $0.000100 | 6% | $3.35 | $3.35 | 1x | $3.35 | 3.69% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Locus Biosciences Comparisons
Industry
Financing
Details
Locus Biosciences Competitors (82)
One of Locus Biosciences’s 82 competitors is CRISPR Therapeutics, a Formerly VC-backed company based in Zug, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| EdiGene | Venture Capital-Backed | Beijing, China | ||||
| Axial Therapeutics | Venture Capital-Backed | Woburn, MA |
Locus Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Locus Biosciences Patents
Locus Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023362887-A1 | Staphylococcus phage compositions and cocktails thereof | Pending | 17-Oct-2022 | ||
| EP-4519287-A1 | Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof | Pending | 04-May-2022 | ||
| US-20230346861-A1 | Phage delivery of anti-inflammatory peptides | Inactive | 05-May-2021 | ||
| US-20240067935-A1 | Altering the normal balance of microbial populations | Pending | 23-Dec-2020 | ||
| CA-3197191-A1 | Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof | Pending | 05-Nov-2020 | C12N15/74 |
Locus Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Locus Biosciences Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CARB-X | University | Minority | ||
| Codon Capital | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority | ||
| Viking Global Investors | Asset Manager | Minority | ||
| Abstract Ventures | Venture Capital | Minority |
Locus Biosciences Investments & Acquisitions (2)
Locus Biosciences’s most recent deal was a Merger/Acquisition with EpiBiome for . The deal was made on 17-Jul-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EpiBiome | 17-Jul-2018 | Merger/Acquisition | Drug Discovery | ||
| EpiBiome (Bacteriophage discovery platform) | 17-Jul-2018 | Corporate Asset Purchase | Buildings and Property |
Locus Biosciences FAQs
-
When was Locus Biosciences founded?
Locus Biosciences was founded in 2015.
-
Where is Locus Biosciences headquartered?
Locus Biosciences is headquartered in Morrisville, NC.
-
What is the size of Locus Biosciences?
Locus Biosciences has 63 total employees.
-
What industry is Locus Biosciences in?
Locus Biosciences’s primary industry is Drug Discovery.
-
Is Locus Biosciences a private or public company?
Locus Biosciences is a Private company.
-
What is Locus Biosciences’s current revenue?
The current revenue for Locus Biosciences is .
-
How much funding has Locus Biosciences raised over time?
Locus Biosciences has raised $105M.
-
Who are Locus Biosciences’s investors?
CARB-X, Codon Capital, Johnson & Johnson Innovation - JJDC, Viking Global Investors, and Abstract Ventures are 5 of 13 investors who have invested in Locus Biosciences.
-
Who are Locus Biosciences’s competitors?
CRISPR Therapeutics, Immunocore Holdings, Vedanta Biosciences, EdiGene, and Axial Therapeutics are some of the 82 competitors of Locus Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
